MedTrace Logo

Metoclopramide vs Placebo for Prevention of Pneumonia in Acute Stroke

NCT04873297 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2021-10-19

No results posted yet for this study

Summary

Pneumonia is a major cause of mortality and morbidity in patients with acute stroke fed via nasogastric tubes and may be because of vomiting and gastro-esophageal regurgitation. The aim of the study was to assess whether regular treatment with metoclopramide, a D2-receptor antagonist with antiemetic and gastric prokinetic actions, could reduce the rate of pneumonia.

Conditions

  • Acute Stroke
  • Aspiration Pneumonia

Interventions

DRUG

Metoclopramide 10mg

Tab. Metoclopramide 10mg TDS via NG tube

DRUG

Placebo

Placebo 10 ml of plain water Via NG

Sponsors & Collaborators

  • Shaheed Zulfiqar Ali Bhutto Medical University

    lead OTHER

Principal Investigators

  • Muhammad Hassan, MD · Shaheed Zulfiqar Ali Bhutto Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-02
Primary Completion
2021-10-02
Completion
2021-10-02

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04873297 on ClinicalTrials.gov